Compounders Research Compare

Propanc Biopharma, Inc.(PPCB)

Biotechnology · Camberwell, VIC

$0.53+0.03 (+5.00%)

Delayed quote: Oct 6, 2026, 12:25 PM EDT

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.

Camberwell, VIC

2 employees

www.propanc.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: James Nathanielsz

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T16:28:22.996Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:28:22.996Z.

Quote observation: 2026-10-06T16:25:13.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,196,145
Total debt · period ending 2026-06-30: 509,116
Cash · period ending 2026-06-30: 832,006
TTM free cash flow · period ending 2026-06-30: -5,797,850

FMP input reference: ee26685a5d6dda55be8f646f5bdd6a865e7c0271b97e419ee039990db4d6ed05

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

PPCB EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

PPCB Competitors' EV/FCF Ratio

Propanc Biopharma, Inc.

Current

Market Cap

$1.20M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Jupiter Neurosciences, Inc.

Market Cap

$1.20M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IM Cannabis Corp.

Market Cap

$1.15M

EV/FCF Ratio

N/A

TTM Avg

8.03x

3Y Avg

7.79x

5Y Avg

7.79x

Cellyan Biotechnology Co., Ltd

Market Cap

$1.10M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NewcelX Ltd.

Market Cap

$1.33M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Clearmind Medicine Inc.

Market Cap

$1.06M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Genprex, Inc.

Market Cap

$1.34M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aspire Biopharma Holdings, Inc.

Market Cap

$1.03M

EV/FCF Ratio

N/A

TTM Avg

60793.51x

3Y Avg

60793.51x

5Y Avg

60793.51x

Artelo Biosciences, Inc.

Market Cap

$1.38M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NEXGEL, Inc.

Market Cap

$1.43M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Propanc Biopharma, Inc. (PPCB)	$1.20M	N/A	N/A	N/A	N/A
Jupiter Neurosciences, Inc. (JUNS)vs ›	$1.20M	N/A	N/A	N/A	N/A
IM Cannabis Corp. (IMCC)vs ›	$1.15M	N/A	8.03x	7.79x	7.79x
Cellyan Biotechnology Co., Ltd (HKPD)vs ›	$1.10M	N/A	N/A	N/A	N/A
NewcelX Ltd. (NCEL)vs ›	$1.33M	N/A	N/A	N/A	N/A
Clearmind Medicine Inc. (CMND)vs ›	$1.06M	N/A	N/A	N/A	N/A
Genprex, Inc. (GNPX)vs ›	$1.34M	N/A	N/A	N/A	N/A
Aspire Biopharma Holdings, Inc. (ASBP)vs ›	$1.03M	N/A	60793.51x	60793.51x	60793.51x
Artelo Biosciences, Inc. (ARTL)vs ›	$1.38M	N/A	N/A	N/A	N/A
NEXGEL, Inc. (NXGL)vs ›	$1.43M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics